Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 5/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641433 | 0.84 | PKM (0.38) | HTR2AHTR2CKMOPKMGRM2 | |
| SCHEMBL1981526 | 0.79 | KMO (0.46) | KMOPDE4BPDE4D | |
| SCHEMBL12601124 | 0.78 | HTR2A (0.38) | HTR2AHTR2CKMO | |
| SCHEMBL8804551 | 0.77 | PKM (0.36) | KMOPKMGRM2PDE4BPDE4D | |
| SCHEMBL21780866 | 0.77 | KMO (0.46) | HTR2AHTR2CKMOPKMSLC9A1 | |
| SCHEMBL13641449 | 0.76 | HTR2A (0.40) | HTR2AHTR2CKMOPDE4BPDE4D | |
| SCHEMBL14155060 | 0.72 | KMO (0.66) | HTR2AHTR2CKMOHTR2B | |
| SCHEMBL31602858 | 0.72 | HTR2A (0.41) | HTR2AHTR2CKMOMAOBEGFR | |
| SCHEMBL17848050 | 0.71 | PIK3CB (0.44) | PKM | |
| SCHEMBL861732 | 0.69 | CYP1A2 (0.57) | KMOSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | HTR2A 996/4885HTR2C 1151/4885KMO 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.